English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Antinuclear antibodies (ANA) are present in a large number of systemic autoimmune diseases (EAS), being a highly requested study in clinical practice, as well as a technique in high demand in clinical laboratories. Although in the last decade there has been a great regional and international effort to agree and standardize the test, in our country the laboratories show disparity in the techniques used and the initial dilution of screening. Likewise, in clinical practice, the indication of the test is often not well directed. In the Uruguayan Congress of Clinical Pathology of 2016, a Continuing Medical Education Course on the Use of ANA was given and once again the need to standardize both clinical and laboratory practices around the test was recognized. In order to generate a 1st Uruguayan Consensus on ANA, a working group was formed to discuss the issues to be agreed upon.

revista médica del uruguay

1er Consenso Uruguayo de Anticuerpos Antinucleares Departamento de Laboratorio Clínico, Unidad de Enfermedades Autoinmunes Sistémicas, Hospital de Clínicas Unidad de Enfermedades Autoinmunes Sistémicas, Hospital Pasteur